Benjamin L. Judson, MD
“This (adverse cardiac effects of chemotherapy) is a difficult problem to address because the side effects of chemotherapy in terms of its impact on the heart show up many years, sometimes decades, later. So that makes it harder to study and treat. It’s a real problem,” commented session co-moderator Benjamin L. Judson, MD, Associate Professor of Surgery (Otolaryngology), Yale Head and Neck Cancer Program, New Haven, Connecticut.
“I think this study shows some promising early data. But a lot more needs to be known about the safety of this treatment in patients who are on active treatment for cancer,” he said in an interview. “So this is not ready for prime time.” ■
Disclosure: Dr. Judson reported no potential conflicts of interest.
The anabolic hormone testosterone may lessen the early adverse cardiovascular effects of chemotherapy and chemoradiation for advanced or recurrent cancer, according to a randomized controlled trial reported at the 9th International Conference on Head and Neck Cancer.1
Among the patients studied,...